Ironwood Pharmaceuticals (IRWD) Projected to Post Quarterly Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) is expected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.08 per share and revenue of $74.22 million for the quarter. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:30 AM ET.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The company had revenue of $85.24 million during the quarter, compared to the consensus estimate of $62.02 million. On average, analysts expect Ironwood Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ironwood Pharmaceuticals Trading Up 0.5%

NASDAQ IRWD opened at $1.87 on Wednesday. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $5.13. The company has a 50 day moving average of $1.44 and a 200-day moving average of $1.02. The company has a market cap of $303.75 million, a price-to-earnings ratio of -37.39 and a beta of 0.30.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Finally, Zacks Research upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $4.94.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in IRWD. Millennium Management LLC raised its position in shares of Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after buying an additional 4,140,439 shares in the last quarter. AQR Capital Management LLC increased its position in Ironwood Pharmaceuticals by 144.3% during the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after purchasing an additional 3,641,762 shares in the last quarter. Marshall Wace LLP increased its position in Ironwood Pharmaceuticals by 616.3% during the 2nd quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 3,436,036 shares in the last quarter. Jane Street Group LLC increased its position in Ironwood Pharmaceuticals by 740.5% during the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after purchasing an additional 3,092,475 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Ironwood Pharmaceuticals by 135.1% during the 2nd quarter. Bank of America Corp DE now owns 3,357,872 shares of the biotechnology company’s stock worth $2,408,000 after purchasing an additional 1,929,356 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.